Financial Survey: ViewRay (VRAY) & The Competition
ViewRay (NASDAQ: VRAY) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare ViewRay to similar businesses based off the strength of its risk, profitability, institutional ownership, analyst recommendations, earnings, dividends and valuation.
Institutional & Insider Ownership
53.7% of ViewRay shares are owned by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 62.8% of ViewRay shares are owned by company insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
ViewRay has a beta of -0.35, suggesting that its stock price is 135% less volatile than the S&P 500. Comparatively, ViewRay’s competitors have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for ViewRay and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ViewRay presently has a consensus price target of $10.00, suggesting a potential upside of 63.13%. All “Advanced Medical Equipment & Technology” companies have a potential downside of 20.97%. Given ViewRay’s stronger consensus rating and higher probable upside, equities research analysts plainly believe ViewRay is more favorable than its competitors.
Valuation and Earnings
This table compares ViewRay and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|ViewRay||$18.41 million||-$43.16 million||-4.75|
|ViewRay Competitors||$2.01 billion||$429.46 million||-57.72|
ViewRay’s competitors have higher revenue and earnings than ViewRay. ViewRay is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently the more expensive than other companies in its industry.
This table compares ViewRay and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with MarketBeat.com's FREE daily email newsletter.